scholarly journals Evaluation of Urinary Exosomes’ Presence for Liquid Biopsy of Clear Cell Renal Cell Carcinoma (Preprint)

2020 ◽  
Author(s):  
Guorong Li ◽  
Nora Mallouk ◽  
Pascale Flandrin ◽  
Arnauld Garcin ◽  
Claude Lambert ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Liquid Biopsy ◽  
Renal Cell ◽  
Clear Cell ◽  
Treatment Decision ◽  
Surgical Excision ◽  
Abdominal Ultrasound ◽  
Cell Renal Cell Carcinoma ◽  
Tissue Biopsy

BACKGROUND About 70-80% of kidney cancers are clear cell renal cell carcinomas (CCRCC). Patient management is based on imaging (abdominal ultrasound and computerized tomography), surgical excision of the tumor and pathological analysis. A tissue biopsy is therefore necessary to confirm the diagnosis and avoid unnecessary nephrectomy. For metastatic cancers, a tissue biopsy is essential for establishing the targeted therapy. This biopsy of tumor material is invasive and painful. Other techniques like liquid biopsy would help reduce tissue biopsy. The development of a simple biological test for diagnosis is essential. CA9 is a powerful marker for the diagnosis of clear cell renal cell carcinoma (CCRCC). Exosome has become a major source of liquid biopsy because they carry tumor protein, RNA and lipids. Urine is the most convenient biological liquid. OBJECTIVE The aim of this study (PEP-C) is mainly to determine whether it is possible to detect urinary exosomal CA9 for the molecular diagnosis of CCRCC. METHODS This study will include 60 patients with CCRCC and 40 non-cancer patients. Exosomes will be isolated from urine samples and exosomal CA9 will be detected by transmission electron microscopy, flow cytometry and RT-qPCR. RESULTS This study is currently underway with funding support from the CHU Saint-Etienne of France. CONCLUSIONS We expect to demonstrate that urinary exosomal CA9 could be a novel liquid biopsy to diagnose CCRCC and to guide clinicians in treatment decision-making. CLINICALTRIAL NCT04053855. Registered August 13, 2019,

scholarly journals Liquid biopsy in clear cell renal cell carcinoma: urinary miR-210-3p as emerging specific biomarker

2020 ◽  
Vol 20 ◽  
pp. S122
Author(s):  
M. Costantini ◽  
V. Petrozza ◽  
C. Tito ◽  
L.M. Giammusso ◽  
V. Sorrentino ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Liquid Biopsy ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Liquid biopsy in clear cell renal cell carcinoma: Urinary miR-210-3p as emerging specific biomarker

2020 ◽  
Vol 19 ◽  
pp. e1488-e1489
Author(s):  
M. Costantini ◽  
V. Petrozza ◽  
C. Tito ◽  
L.M. Giammusso ◽  
V. Sorrentino ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Liquid Biopsy ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma

ESMO Open ◽  
2020 ◽  
Vol 5 (Suppl 3) ◽  
pp. e000852 ◽  
Author(s):  
Stefanie Aeppli ◽  
Eric Innocents Eboulet ◽  
Tim Eisen ◽  
Bernard Escudier ◽  
Stefanie Fischer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Online Survey ◽  
Kinase Inhibitors ◽  
Clear Cell ◽  
Treatment Decision ◽  
Risk Category ◽  
Cell Renal Cell Carcinoma ◽  
Risk Patients

BackgroundThe coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of care in the majority of metastatic clear cell renal cell carcinoma (mccRCC) patients. It remains unclear whether therapies should be modified in response to the COVID-19 pandemic.MethodsWe performed an online survey among physicians involved in the treatment of mccRCC, and 41 experts responded. Questions focused on criteria relevant for treatment decision outside the pandemic and the modifications of systemic therapy during COVID-19.FindingsFor the majority of experts (73%), the combination of International metastatic renal cell carcinoma Database Consortium (IMDC) risk category and patient fitness are two important factors for decision-making. The main treatment choice in fit, favourable risk patients outside the pandemic is pembrolizumab/axitinib for 53%, avelumab/axitinib, sunitinib or pazopanib for 13% of experts each. During the pandemic, ICI-containing regimens are chosen less often in favour of a tyrosine kinase inhibitors (TKI) monotherapy, mainly sunitinib or pazopanib (35%).In fit, intermediate/poor-risk patients outside the pandemic, over 80% of experts choose ipilimumab/nivolumab, in contrast to only 41% of physicians during COVID-19, instead more TKI monotherapies are given. In patients responding to established therapies with ICI/ICI or ICI/TKI combinations, most participants modify treatment regimen by extending cycle length, holding one ICI or even both.ConclusionmccRCC treatment modifications in light of the coronavirus pandemic are variable, with a shift from ICI/ICI to ICI/TKI or TKI monotherapy.

scholarly journals MP08-05 LIQUID BIOPSY IN CLEAR CELL RENAL CELL CARCINOMA

2020 ◽  
Vol 203 ◽  
pp. e107
Author(s):  
Manuela Costantini* ◽  
Vincenzo Petrozza ◽  
Claudia Tito ◽  
Laura maria Giammusso ◽  
Veronica Sorrentino ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Liquid Biopsy ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

638: Macroscopic Tumor Necrosis is a Prognostic Indicator for Non-Metastatic Clear Cell Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 214-214
Author(s):  
Sung Kyu Hong ◽  
Byung Kyu Han ◽  
In Ho Chang ◽  
June Hyun Han ◽  
Ji Hyung Yu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Necrosis ◽  
Clear Cell ◽  
Prognostic Indicator ◽  
Cell Renal Cell Carcinoma ◽  
Macroscopic Tumor

Rare localization of renal cell carcinoma metastases in the paranasal sinuses and breast: a case report

2019 ◽  
Vol 22 (6) ◽  
pp. 13-22
Author(s):  
E. V. Kryaneva ◽  
N. A. Rubtsova ◽  
A. V. Levshakova ◽  
A. I. Khalimon ◽  
A. V. Leontyev ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paranasal Sinuses ◽  
Renal Cell ◽  
Clinical Case ◽  
Clear Cell ◽  
Malignant Tumors ◽  
Metastatic Potential ◽  
Cell Renal Cell Carcinoma ◽  
Metastatic Lesions

This article presents a clinical case demonsratinga high metastatic potential of clear cell renal cell carcinoma combined with atypical metastases to breast and paranasal sinuses. The prevalence of metastatic lesions to the breast and paranasal sinuses in various malignant tumors depending on their morphological forms is analyzed. The authors present an analysis of data published for the last 30 years. The optimal diagnostic algorithms to detect the progression of renal cell carcinoma and to evaluate the effectiveness of the treatment are considered.

Sign in / Sign up

Export Citation Format

Share Document